Clinical Trial: Bevacizumab and Erlotinib in the Treatment of Patients With Carcinoma of Unknown Primary Site

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: A Phase II Trial of Bevacizumab and Erlotinib in the Treatment of Patients With Carcinoma of Unknown Primary Site

Brief Summary: This trial will investigate the combination of bevacizumab, and erlotinib in patients with adenocarcinoma or poorly differentiated carcinoma of unknown primary site. Bevacizumab and erlotinib are relatively well-tolerated and have non-overlapping toxicity profiles. This trial will be one of the first clinical trials to evaluate a combination of targeted agents in the treatment of a solid tumor.

Detailed Summary:

Upon determination of eligibility, patients will be receive:

  • Bevacizumab + Erlotinib

Sponsor: SCRI Development Innovations, LLC

Current Primary Outcome: Overall response rate

Original Primary Outcome: Same as current

Current Secondary Outcome:

  • Time to progression
  • Overall survival
  • Overall tolerability
  • Overall toxicity


Original Secondary Outcome: Same as current

Information By: SCRI Development Innovations, LLC

Dates:
Date Received: September 12, 2005
Date Started: April 2004
Date Completion:
Last Updated: September 15, 2010
Last Verified: September 2010